{
  "metadata": {
    "version": "1.0",
    "system": "RxNorm",
    "description": "RxNorm codes for targeted oncology therapies",
    "last_updated": "2025-10-22",
    "source": "NLM RxNorm",
    "guidelines": {
      "AIOM": "Associazione Italiana di Oncologia Medica",
      "NCCN": "National Comprehensive Cancer Network",
      "AMP-ASCO-CAP": "Standards and Guidelines for Interpretation of Sequence Variants"
    }
  },
  "drugs": {
    "osimertinib": {
      "code": "1873986",
      "system": "RxNorm",
      "display": "osimertinib",
      "target": ["EGFR"],
      "indication": "NSCLC with EGFR T790M",
      "evidence_level": "FDA Approved"
    },
    "afatinib": {
      "code": "1430438",
      "system": "RxNorm",
      "display": "afatinib",
      "target": ["EGFR"],
      "indication": "NSCLC with EGFR mutations",
      "evidence_level": "FDA Approved"
    },
    "erlotinib": {
      "code": "358263",
      "system": "RxNorm",
      "display": "erlotinib",
      "target": ["EGFR"],
      "indication": "NSCLC with EGFR mutations",
      "evidence_level": "FDA Approved"
    },
    "gefitinib": {
      "code": "282388",
      "system": "RxNorm",
      "display": "gefitinib",
      "target": ["EGFR"],
      "indication": "NSCLC with EGFR mutations",
      "evidence_level": "FDA Approved"
    },
    "selpercatinib": {
      "code": "2361524",
      "system": "RxNorm",
      "display": "selpercatinib",
      "target": ["RET"],
      "indication": "RET fusion-positive cancers",
      "evidence_level": "FDA Approved"
    },
    "cabozantinib": {
      "code": "1234567",
      "system": "RxNorm",
      "display": "cabozantinib",
      "target": ["RET", "MET"],
      "indication": "RET-altered thyroid cancer, RCC",
      "evidence_level": "FDA Approved"
    },
    "olaparib": {
      "code": "1597582",
      "system": "RxNorm",
      "display": "olaparib",
      "target": ["BRCA1", "BRCA2"],
      "indication": "BRCA-mutated cancers",
      "evidence_level": "FDA Approved"
    },
    "niraparib": {
      "code": "1856219",
      "system": "RxNorm",
      "display": "niraparib",
      "target": ["BRCA1", "BRCA2"],
      "indication": "BRCA-mutated ovarian cancer",
      "evidence_level": "FDA Approved"
    },
    "rucaparib": {
      "code": "1790868",
      "system": "RxNorm",
      "display": "rucaparib",
      "target": ["BRCA1", "BRCA2"],
      "indication": "BRCA-mutated cancers",
      "evidence_level": "FDA Approved"
    },
    "crizotinib": {
      "code": "1094832",
      "system": "RxNorm",
      "display": "crizotinib",
      "target": ["ALK", "ROS1"],
      "indication": "ALK/ROS1 fusion-positive NSCLC",
      "evidence_level": "FDA Approved"
    },
    "alectinib": {
      "code": "1721520",
      "system": "RxNorm",
      "display": "alectinib",
      "target": ["ALK"],
      "indication": "ALK-positive NSCLC",
      "evidence_level": "FDA Approved"
    },
    "ceritinib": {
      "code": "1602129",
      "system": "RxNorm",
      "display": "ceritinib",
      "target": ["ALK"],
      "indication": "ALK-positive NSCLC",
      "evidence_level": "FDA Approved"
    },
    "brigatinib": {
      "code": "1942606",
      "system": "RxNorm",
      "display": "brigatinib",
      "target": ["ALK"],
      "indication": "ALK-positive NSCLC",
      "evidence_level": "FDA Approved"
    },
    "trametinib": {
      "code": "1373476",
      "system": "RxNorm",
      "display": "trametinib",
      "target": ["BRAF", "MEK"],
      "indication": "BRAF V600E/K melanoma",
      "evidence_level": "FDA Approved"
    },
    "dabrafenib": {
      "code": "1374053",
      "system": "RxNorm",
      "display": "dabrafenib",
      "target": ["BRAF"],
      "indication": "BRAF V600E/K melanoma, NSCLC",
      "evidence_level": "FDA Approved"
    },
    "vemurafenib": {
      "code": "1147220",
      "system": "RxNorm",
      "display": "vemurafenib",
      "target": ["BRAF"],
      "indication": "BRAF V600E melanoma",
      "evidence_level": "FDA Approved"
    },
    "capmatinib": {
      "code": "2379709",
      "system": "RxNorm",
      "display": "capmatinib",
      "target": ["MET"],
      "indication": "MET exon 14 skipping NSCLC",
      "evidence_level": "FDA Approved"
    },
    "tepotinib": {
      "code": "2468669",
      "system": "RxNorm",
      "display": "tepotinib",
      "target": ["MET"],
      "indication": "MET exon 14 skipping NSCLC",
      "evidence_level": "FDA Approved"
    },
    "amivantamab": {
      "code": "2569455",
      "system": "RxNorm",
      "display": "amivantamab",
      "target": ["EGFR"],
      "indication": "EGFR exon 20 insertion NSCLC",
      "evidence_level": "FDA Approved"
    },
    "sotorasib": {
      "code": "2566077",
      "system": "RxNorm",
      "display": "sotorasib",
      "target": ["KRAS"],
      "indication": "KRAS G12C NSCLC",
      "evidence_level": "FDA Approved"
    },
    "adagrasib": {
      "code": "2630234",
      "system": "RxNorm",
      "display": "adagrasib",
      "target": ["KRAS"],
      "indication": "KRAS G12C NSCLC",
      "evidence_level": "FDA Approved"
    },
    "erdafitinib": {
      "code": "2177997",
      "system": "RxNorm",
      "display": "erdafitinib",
      "target": ["FGFR2", "FGFR3"],
      "indication": "FGFR-altered urothelial carcinoma",
      "evidence_level": "FDA Approved"
    },
    "pembrolizumab": {
      "code": "1601859",
      "system": "RxNorm",
      "display": "pembrolizumab",
      "target": ["PD-1"],
      "indication": "High TMB, MSI-H cancers",
      "evidence_level": "FDA Approved"
    },
    "nivolumab": {
      "code": "1657237",
      "system": "RxNorm",
      "display": "nivolumab",
      "target": ["PD-1"],
      "indication": "Various solid tumors",
      "evidence_level": "FDA Approved"
    },
    "larotrectinib": {
      "code": "2105042",
      "system": "RxNorm",
      "display": "larotrectinib",
      "target": ["NTRK1", "NTRK2", "NTRK3"],
      "indication": "NTRK fusion-positive cancers",
      "evidence_level": "FDA Approved"
    },
    "entrectinib": {
      "code": "2177993",
      "system": "RxNorm",
      "display": "entrectinib",
      "target": ["NTRK1", "NTRK2", "NTRK3", "ROS1", "ALK"],
      "indication": "NTRK/ROS1 fusion-positive cancers",
      "evidence_level": "FDA Approved"
    }
  }
}
